PATRICIA MORRIS: Open Payments
NPI 1851931620 · CAIRO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$713 in 34 payments from 9 companies in 2025. Trend: 2023 $140 · 2024 $90 · 2025 $713
Food & beverage: $713
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $143 |
| Neurocrine BioSciences, Inc. | 5 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $114 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $95 |
| E.R. Squibb & Sons, L.L.C. | 4 | $85 |
| Alkermes, Inc. | 3 | $62 |
| ABBVIE INC. | 3 | $54 |
| Lundbeck LLC | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: INGREZZA, FANAPT, CAPLYTA, AUSTEDO XR, COBENFY, LYBALVI, UZEDY, VRAYLAR.
Industry payments across GA — which companies pay providers there.
